IDiyas

For the Inventor, By the Inventor

North Wales, PA, United States of America

Jacob M Hoffman, Jr

USPTO Granted Patents = 14

Average Co-Inventor Count = 2.1

ph-index = 9

Forward Citations = 267(Granted Patents)


Location History:

  • North Wales, PA (US) (1979 - 1994)
  • Landsale, PA (US) (1996)

Company Filing History:

goldMedal14 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1979-1996

Loading Chart...
14 patents (USPTO):Explore Patents
1. 5527819 - Inhibitors of HIV reverse transcriptase (1996-06-18),
2. 5308854 - Inhibitors of HIV reverse transcriptase (1994-05-03),
3. 4946859 - 4-(2-methyl-2-hydroxypropylamino)-5,6-dihydrot (1990-08-07),
4. 4808595 - Furopyridine sulfonamides and their opthalmological compositions (1989-02-28),
5. 4731368 - Thienopyridine sulfonamides and their ophthalmological formulation (1988-03-15),
6. 4505923 - Ethers of hydroxybenzothiazole-2-sulfonamide for the topical treatment (1985-03-19),
7. 4497810 - Thiatriazine dioxides as gastric anti-secretory agents (1985-02-05),
8. 4496737 - Process for preparing sulfamylamidine antisecretory agents (1985-01-29),
9. 4490533 - Aminoalkyl pyridine derivatives (1984-12-25),
10. 4420615 - Substituted pyridopyrimidines as gastric secretion inhibitors (1983-12-13),
11. 4229456 - Substituted naphthyridinones and processes for their preparations (1980-10-21),
12. 4220654 - Cyclic imidazole cyanoguanidines (1980-09-02),
13. 4203988 - Pyridinyl ureas and pharmaceutical use (1980-05-20),
14. 4133885 - Substituted naphthyridinones (1979-01-09),

Title: **Innovative Contributions of Jacob M Hoffman, Jr. in HIV Research**

Introduction

Jacob M Hoffman, Jr., based in North Wales, PA, is a notable inventor recognized for his significant contributions to the field of pharmaceuticals, particularly in the development of therapies targeting HIV/AIDS. With a remarkable portfolio of 14 patents, Hoffman has dedicated his career to finding innovative solutions to complex health challenges.

Latest Patents

Hoffman's latest patents focus on inhibitors of HIV reverse transcriptase. His novel indole compounds and aminopyridones have shown promise in both the prevention and treatment of HIV infections. These compounds function as potential pharmaceutical agents, working alone or in combination with other antiviral drugs, anti-infectives, immunomodulators, antibiotics, or vaccines. The patents also describe methodologies for treating AIDS and protecting against HIV infection, further emphasizing Hoffman's role as a leader in this critical area of research.

Career Highlights

Hoffman is currently affiliated with Merck & Company, Inc., where his innovative approach to pharmaceutical development has led to groundbreaking research and advancements in HIV treatment. His work is vital in the ongoing battle against one of the world's most persistent health issues, showcasing his commitment to improving patient outcomes through scientific innovation.

Collaborations

Throughout his career, Hoffman has collaborated with other esteemed professionals in the field, including William A Bolhofer and Edward J Cragoe, Jr. These partnerships have enriched his research endeavors and have enabled the pooling of expertise within the pharmaceutical research community.

Conclusion

Jacob M Hoffman, Jr. exemplifies the essence of innovation in drug development through his dedicated research efforts and successful patents. His contributions to HIV/AIDS treatment demonstrate the profound impact that inventive minds can have on global health challenges. As the pharmaceutical landscape continues to evolve, Hoffman's work remains a beacon of hope for those affected by HIV and AIDS.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…